Abstract:Recent research highlights five potential biomarkers—INHBA, MMP7, PSAT1, SLC7A5, and TGFBI—with elevated levels in colorectal cancer tissues and serum of patients, showing promise for non‐invasive CRC detection. These biomarkers exhibit high diagnostic accuracy, suggesting their potential to improve current diagnostic methods and enhance personalized treatment approaches, though further validation and functional studies are required for larger cohorts. Background The pressing need for reliable biomarkers in colorectal cancer (CRC) diagnosis and prognosis is a major global health concern. Current diagnostic methods rely heavily on invasive procedures like colonoscopy, and existing biomarkers such as Carbohydrate Antigen 19‐9 (CA19‐9) and Carcinoembryonic Antigen (CEA) exhibit limitations in accuracy and specificity. Aims This study aims to identify and validate novel biomarkers that can enhance the early detection and diagnostic precision of CRC while overcoming the shortcomings of conventional biomarkers. Materials and Methods Leveraging advancements in genomic and proteomic technologies, gene expression datasets were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). We identified differentially expressed genes (DEGs) and conducted further analyses, including Gene Ontology (GO) enrichment and Protein‐Protein Interaction (PPI) network construction. Five promising biomarkers—INHBA, MMP7, PSAT1, SLC7A5, and TGFBI—were selected based on their robust performance in Receiver Operating Characteristic (ROC) curve analysis. Serum concentrations of these biomarkers were measured in 200 CRC patients and 100 healthy controls. Results The study revealed significantly elevated expression levels of the selected biomarkers in CRC tissues compared to normal tissues. Additionally, serum concentrations of INHBA, MMP7, PSAT1, SLC7A5, and TGFBI were notably higher in CRC patients than in healthy individuals, with Area Under the Curve (AUC) values ranging from 0.8361 to 0.9869 indicating high diagnostic accuracy. Optimal cutoff values for diagnosis ranged from 38.9 pg/mL to 280.7 pg/mL, yielding sensitivity and specificity values between 74.5% and 92.9%. Discussion The findings underscore the potential of INHBA, MMP7, PSAT1, SLC7A5, and TGFBI as effective non‐invasive biomarkers for CRC detection. Their elevated serum concentrations and robust discriminatory abilities highlight their promise in improving diagnostic accuracy and patient outcomes compared to traditional biomarkers. Conclusion The identification and validation of these novel biomarkers represent a significant advancement in CRC diagnosis and management. Further studies are required to validate their clinical applicability in larger cohorts and to elucidate their functional roles in CRC pathogenesis, ultimately enhancing diagnostic strategies and personalized treatment approaches.

Serum IGFBP-1 as a promising diagnostic and prognostic biomarker for colorectal cancer

Igfbp-Rp1, A Potential Molecule Associated with Colon Cancer Differentiation

Diagnostic Value of Serum Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) in Colorectal Cancer

Clinical significance of serum IGFBP-3 in colorectal cancer.

RBP4 and THBS2 Are Serum Biomarkers for Diagnosis of Colorectal Cancer

IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis.

IGFBP7 Plays a Potential Tumor Suppressor Role Against Colorectal Carcinogenesis with Its Expression Associated with DNA Hypomethylation of Exon 1

Investigation of Cell Free BIRC5 Mrna As a Serum Diagnostic and Prognostic Biomarker for Colorectal Cancer.

Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer

A Serum Pirna Signature As Promising Non-Invasive Diagnostic and Prognostic Biomarkers for Colorectal Cancer.

Serum Pirna-54265 is a New Biomarker for Early Detection and Clinical Surveillance of Human Colorectal Cancer

Circulating Basophil Count As a Prognostic Marker of Tumor Aggressiveness and Survival Outcomes in Colorectal Cancer.

Elevated Serum Antibodies Against Insulin-Like Growth Factor-Binding Protein-2 Allow Detecting Early-Stage Cancers: Evidences from Glioma and Colorectal Carcinoma Studies.

The Role of Insulin-Like Growth Factor 1 and Its Receptor in the Formation and Development of Colorectal Carcinoma.

Increased Igf2bp3 Expression Promotes The Aggressive Phenotypes Of Colorectal Cancer Cells In Vitro And Vivo

Detection of the Differentially Expressed Gene IGF-binding Protein-Related Protein-1 and Analysis of Its Relationship to Fasting Glucose in Chinese Colorectal Cancer Patients.

Identification and Validation of Serum Biomarkers to Improve Colorectal Cancer Diagnosis

The clinicopathological and prognostic significances of IGF-1R and Livin expression in patients with colorectal cancer

Value of serum FBLN1 detection in diagnosis and prognosis prediction of colorectal cancer

Serum insulin-like growth factor binding protein-3 as a potential biomarker for diagnosis and prognosis of oesophageal squamous cell carcinoma

Prognostic and diagnostic value of circulating IGFBP2 in pancreatic cancer